Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
about
Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemiaPrognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyDNA sequencing of a cytogenetically normal acute myeloid leukaemia genomeAcute Myeloid Leukemia: A Concise ReviewMolecular landscape of acute myeloid leukemia in younger adults and its clinical relevanceAllogeneic stem cell transplantation in first complete remissionThe prognostic and functional role of microRNAs in acute myeloid leukemiaFLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B studyFavorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaRUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.Novel Prognostic and Therapeutic Mutations in Acute Myeloid LeukemiaTargeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and TreatmentClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewIntegrative meta-analysis of differential gene expression in acute myeloid leukemiaGenetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemiaAssociation of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Competing views on cancer.Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.Functional proteomic profiling of AML predicts response and survivalShortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaFLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyMutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia.Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosisThe effect of aqueous cinnamon extract on the apoptotic process in acute myeloid leukemia HL-60 cells.Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remissionMolecular signatures in acute myeloid leukemia.The effect of calcium channel blockers on the outcome of acute myeloid leukemia.Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
P2860
Q24612217-471CE691-8B42-4DDA-BC00-6A088E21F1D9Q24643738-D4E75344-9B05-498D-99B1-CCC24784E625Q24644436-8C135CF4-F8B6-4565-A631-035C3B4715A5Q26766719-04C4363E-C857-447D-9C00-4F0E256383FFQ26776393-8A39F440-231A-4952-8C4A-FE88C41A188FQ26996818-2E9DAAD6-3397-4156-BAA1-D457A36FF007Q27693865-56D4ADD3-6C20-4F8F-BB3F-7BDFF0CBD155Q27851415-5784D83C-A0BB-4678-8E0C-F0B6BA6CF3A7Q27851436-B52B72F8-68DF-407B-8ED5-FA23741B36DEQ27851545-AFA5AE63-94D6-4DCC-8D40-F07D653947C5Q27851621-BBA213B2-2BD3-4060-BAF7-5404374E1995Q27851679-845ACC6D-AE20-4149-AF29-86301D321829Q27851713-EE212AC0-5355-4FD9-9D0D-2856AF984A8EQ27851839-409AA13F-69E8-42D5-9B99-A1F11FFFD3E8Q27853009-7CF2626E-83BD-4DAB-BB6C-556EA5600364Q28075654-78E020C3-9227-4B92-BE15-4B77586082F2Q28076462-6FDF6718-0A85-4E10-B6F5-B0F395632097Q28301344-93CA810A-AB63-4FB3-9167-0ECE736BBC97Q33538043-3253B4D6-1736-43A4-8D72-87C77EE28D9DQ33555627-939F9029-DCD2-4012-AFFC-18E87796807AQ33782633-E424196C-74D3-4B94-83BE-6E5A2D9E801EQ33856839-9789774A-07DB-4487-819E-17DF3F80C8AAQ33873844-C8FD7814-1866-46AE-864E-D6D6ACD2A061Q33880813-A46FB204-A478-43AC-AD25-69BF8AE3D8CDQ33897586-49F60C7B-FE68-4EC1-A167-7DC7287DF59FQ34060169-9A71F22E-56CE-48A2-848A-C8E3B7AD4194Q34097586-321EBE01-66D9-44D4-B276-3C551E8BC94EQ34184598-D9413B20-FCE7-42E2-83AC-71FC4D181CE1Q34193514-93F92C92-F00D-461D-85D1-BF84688D4A37Q34193684-A7E9107A-2D01-43F0-AE87-061795D36CC2Q34197535-FEF519F6-91A1-4F07-87A8-CCB654D2F2EEQ34310561-2DF9BF91-EEFA-419E-A32D-70F17AFDA01FQ34347935-850FAA18-EBE1-4C7D-A318-04DB9ACED62DQ34349257-9F1FAE38-C3E5-419D-80A8-77B79E549F11Q34366744-C4D13672-0F0E-46F5-BBB7-43C4BD2B9EC4Q34388734-50FDF9DA-F2A6-4FDE-82CE-92E6A792280BQ34401926-78957CE4-5861-424B-BFC0-605A63FA214EQ34403639-C1F3B8F5-FE7E-43ED-80BF-213624C3BEAEQ34422254-25241BDB-F0E9-4702-A1F0-81AAEFDC2D17Q34477821-0977CAB6-025D-41EC-9E31-D3D28B2253C2
P2860
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Clinical relevance of mutation ...... ized molecular classification?
@ast
Clinical relevance of mutation ...... ized molecular classification?
@en
type
label
Clinical relevance of mutation ...... ized molecular classification?
@ast
Clinical relevance of mutation ...... ized molecular classification?
@en
prefLabel
Clinical relevance of mutation ...... ized molecular classification?
@ast
Clinical relevance of mutation ...... ized molecular classification?
@en
P2860
P50
P1433
P1476
Clinical relevance of mutation ...... ized molecular classification?
@en
P2093
Peter Paschka
Susan P Whitman
P2860
P304
P356
10.1182/BLOOD-2006-06-001149
P407
P577
2006-09-07T00:00:00Z